KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.

Adv Sci (Weinh) · 2025-Dec · PMID 41287887

Panel B提取失败待 EXE 对齐验证

Overall survival

Figure 5 Dynamic change of tumor‐informed ctDNA status predicts PFS and OS as a complementary method to imaging. A. Schema of analysis. B‐C. Kaplan–Meier curves comparing overall survival (OS) and progression‐free survival (PFS) between different ctDNA dynamic change groups among patients who were treated with ICI‐chemo in the tumor‐informed ctDNA positive group. The HRs, corresponding 95% CIs, and statistical significance of the difference between the groups were computed using the Cox proportional hazards model. D‐E. Kaplan–Meier curves comparing overall survival (OS) and progression‐free survival (PFS) in patients who were treated with ICI‐chemo stratified by radiographic response in on‐treatment ctDNA‐negative (baseline negative or turned negative at C3D1) and on‐treatment ctDNA‐positive (baseline positive or turned positive at C3D1) populations. P values were calculated by the log‐rank test.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.00
质量通过否
预期曲线2
实际曲线0
X 范围-
Y 范围-
No curves extracted

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0failed待验证02026-07-23T17:10:54+00:00